FUTURE 3 Study Extension (FUTURE 3 Ext)

NCT01338415 PHASE3 COMPLETED Results posted

The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).

Details

Lead sponsor	Actelion
Phase	PHASE3
Status	COMPLETED
Enrolment	58
Start date	Tue Mar 08 2011 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri May 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Pulmonary Arterial Hypertension

Interventions

• Bosentan

Countries

France, Italy, South Africa, Russia, Ukraine, India, Serbia, Germany, Hungary, Belarus, Israel, Mexico, Poland, Australia, China, United States, Spain, Czechia